Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Mixed Phase 3 SENTRY trial results in myelofibrosis prompted a decline in Karyopharm (NASDAQ: KPTI) shares on Tuesday. The unclear clinical readout increases uncertainty around the drug's commercial prospects and may pressure valuation and near-term stock volatility.

Analysis

Mixed Phase 3 SENTRY trial results in myelofibrosis prompted a decline in Karyopharm (NASDAQ: KPTI) shares on Tuesday. The unclear clinical readout increases uncertainty around the drug's commercial prospects and may pressure valuation and near-term stock volatility.